Denmark· DK-28104670710
Nulojix
A belatacept product containing belatacept, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Belatacept is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AA28 (belatacept), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Belatacept · ATC L04AA28
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of belatacept costs, country by country.
Normalised to the WHO defined daily dose (12.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Belatacept · price per daily dose (12.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$32.75
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Belatacept
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L04AA28
- ATC class
- Belatacept
- Defined daily dose
- 12.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104670710
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
62 interactions on record for belatacept.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Belatacept · interactions on record
62 records
- 29 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AA28
Belatacept, as other registers publish it.
- PolandNulojixBristol-Myers Squibb Pharma EEIG
- NorwayNulojixBristol-Myers Squibb Pharma EEIG
- FinlandNulojixBristol-Myers Squibb Pharma EEIG
- IcelandNulojixBristol-Myers Squibb Pharma EEIG*
- United StatesNULOJIXE.R. Squibb & Sons, L.L.C.
- CzechiaNULOJIXBristol-Myers Squibb Pharma EEIG, Dublin
- CzechiaNULOJIXBristol-Myers Squibb Pharma EEIG, Dublin
- NetherlandsNulojix 25 mg/ml, poeder voor concentraat voor oplossing voor infusieBristol-Myers Squibb Pharma EEIG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2c12bd9-a6de-4ff6-bc8b-4bbae7929d78 GET /v1/drugs/b2c12bd9-a6de-4ff6-bc8b-4bbae7929d78?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "250 mg",
"auth_role": "MOD",
"dk_drugid": "28104670710",
"substance": "Belatacept",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "40711"
}See everything about belatacept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.